Jasper Therapeutics logo
Jasper Therapeutics
JSPR | NASDAQ
Chart Builder DCF Calculator
$11.77
-$1.91 (-13.96%)
At close: Nov 16, 2026, 4:00 PM ET
$12.41
+$0.64 (+5.44%)
After-hours: Nov 16, 2026, 7:30 PM ET

Jasper Therapeutics Company Profile

Company profile explained

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Key Executives

Name Position
Jeetinder Singh Mahal President, CEO, Interim CFO & Director
Herbert C. Cross Chief Financial Officer & Corporate Secretary
Alex Gray Head of Investor Relations
Gregory F. Keenan Chief Medical Officer
Judith Anne Shizuru Co-Founder, Member of Scientific Advisory Board & Director
Lisa Pitt Senior Vice President of Regulatory Affairs
Matthew E. Ros COO & Interim Corporate Secretary
Matthew Ford Senior Vice President of Human Resources
Thomas G. Wiggans Executive Chairman
Wenru Song Executive VP and Head of R&D

Latest SEC Filings

Date Type Title
Nov 09, 2026 8-K Current Report
Nov 04, 2026 8-K Current Report
Oct 28, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 23, 2026 SC TO-I/A [Amend] Filing
Oct 19, 2026 DEF 14A Filing
Oct 15, 2026 8-K Current Report
Oct 14, 2026 S-3 Filing
Oct 09, 2026 PRE 14A Filing
Oct 07, 2026 8-K Current Report
Oct 07, 2026 SC TO-I Filing
View All SEC Filings ➞
Jasper Therapeutics
Jasper Therapeutics logo
Country United States
IPO Date Jan 10, 2020
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Jeetinder Singh Mahal

Contact Details

2200 Bridge Pkwy Redwood City, California 94065 United States

Stock Details

Ticker Symbol JSPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001788028
CUSIP Number 471871301
ISIN Number US4718713013
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.